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O-9 LOSS OF CSMD1 EXPRESSION DISRUPTS CELL MORPHOL-
OGY AND MAMMARY DUCT FORMATION WHILE ENHANCING
PROLIFERATION, MIGRATION AND INVASION
Mohamed Kamal a,b, Deborah Holliday a, Valerie Speirs a, Carmel
Toomes a, Sandra M. Bell a. a Leeds Institute of Molecular Medicine,
University of Leeds, UK. b Faculty of Science, University of Benha, Egypt
CUB and Sushi multiple domains protein 1 (CSMD1) maps to
8p23, a region deleted in many cancers, and thought to be a
tumour suppressor gene. Loss of CSMD1 expression is associated
with reduced survival in breast cancer patients. CSMD1’s function
is unknown; however, CSMD1‘s structure suggests it is involved in
signal transduction. Here, we have investigated the function of
CSMD1. CSMD1 expression was silenced in MCF10A, MDA-MB-
435 and LNCaP cell lines by shRNA and functional assays were
performed.
Loss of CSMD1 expression disrupted cell morphology and
caused 30% (p < 0.001), 32% (p = 0.03) and 56% (p < 0.001) increase
in cell proliferation of MDA-MB-435, LNCaP and MCF10A, respec-
tively, compared to controls. Also MDA-MB-435 and MCF10A
shCSMD1 cells showed reduced adhesion to matrigel (32%,
p = 0.0005 and 44%, p = 0.0006, respectively), and to fibronectin
(39%, p = 0.004 and 32%, p < 0.001, respectively). Moreover, loss
of CSMD1 expression enhanced cell migration of MDA-MB-435
and MCF10A and caused 33% (p < 0.001) increase in cell invasion
of MCF10A, compared to control. The MCF10A 3D model revealed
that loss of CSMD1 expression resulted in the development of lar-
ger poorly differentiated breast acini and impaired lumen
formation.
Loss of CSMD1 expression induced behaviour consistent with
cellular transformation. Our data supports the concept that
CSMD1 participates in signaling pathways that regulate a range
of key cellular processes involved in the suppression of a trans-
formed phenotype.
doi:10.1016/j.ejcsup.2010.06.010
O-10 HIGH TIMM17A EXPRESSION IS ASSOCIATED WITH POOR
CLINICAL OUTCOME AND UNFAVOURABLE PATHOLOGICAL
PARAMETERS IN HUMAN BREAST CANCER
Mohamed Salhab a, Neill Patani a, Wen Jiang b, Kefah Mokbel a. a St
George’s Hospital, London, UK. b University Department of Surgery,
Cardiff, UK
Introduction: Mitochondrial dysfunction can be associated with
genomic instability and has been implicated in the pathogenesis
of breast cancer (BC). The mitochondrial protein, Translocase of
Inner Mitochondrial Membrane 17 homolog A (TIMM17A) contrib-
utes to a pre-protein import complex, essential for mitochondrial
function. In this study, TIMM17A mRNA expression was evaluated
in benign and malignant breast tissues and correlated with path-
ological and clinical outcomes.
Methods: BC tissues (n = 127) and normal tissues (n = 33) under-
went RNA extraction and reverse transcription, transcript levels
were determined using real-time quantitative PCR and normal-
ized against CK19. Transcript levels were compared and then ana-
lysed against tumour size, tumour grade, oestrogen receptor (ER)
status, nodal involvement, TNM stage, Nottingham Prognostic
Index (NPI) and clinical outcome over a 10 year follow-up period.
Results: Compared to normal tissue, TIMM17A mRNA expres-
sion was higher in BC (p = 0.006), TNM-1 (p = 0.05), TNM-2
(p = 0.034), NPI-2 (p = 0.041), patients with progressive disease
(p = 0.017) and those who died from BC (p = 0.026). Expression
increased with tumour grade; grade 1 versus 2 (p = 0.007), grade
1 versus 3 (p = 0.065, NS) and grade 1 versus 2 and 3 (p = 0.0048).
Higher transcript levels were associated with ER-a positivity
(p = 0.073, NS) and ER-b negativity (p = 0.015). Nodal positivity
was significantly associated with higher transcript levels
(p = 0.046). Compared to disease free patients, TIMM17A expres-
sion was significantly higher in those with progressive disease
and patients who died of BC (p = 0.037). Higher transcript levels
were significantly associated with poorer overall survival after a
median follow-up of 10 years (p = 0.010). TIMM17A expression
emerged as a strong independent predictor of overall survival in
multivariate analysis (p = 0.033).
Conclusion: TIMM17A mRNA expression is significantly associ-
ated with unfavourable pathological parameters including
tumour grade, nodal positivity, TNM stage and NPI; in addition
to adverse clinical outcomes such as progressive disease and
overall survival. TIMM17A offers utility as a prognostic marker
and a novel mitochondrial target for potential therapeutic
strategies.
doi:10.1016/j.ejcsup.2010.06.011
O-11 INHIBITING DNA METHYLATION AND HISTONE
DEACETYLATION ENHANCES RESPONSE TO DOCETAXEL IN
BREAST CANCER CELLS
Lena Kastl, Andrew C. Schofield. School of Medicine and Dentistry,
University of Aberdeen, UK
Introduction: Understanding the mechanisms of drug resis-
tance is important to improve and deliver effective therapy. Epige-
netic modifications like DNA methylation and histone
deacetylation can alter gene expression, due to gene silencing,
and may represent mechanisms of drug resistance.
Methods: Breast cancer cells (MCF-7 and MDA-MB-231), and
their docetaxel-resistant sublines, were treated with either tri-
chostatin A (TSA), 5-aza-20-deoxycytidine (decitabine) or in com-
bination. DNA methyltransferase activity and global
methylation were measured by ELISA-based assays, and histone
acetylation levels were measured by western blot. Response to
docetaxel of cells treated with inhibitors was measured using cell
viability assay. Gene expression analysis was performed using a
microarray-based quantitative PCR system. Western analysis
was used to validate gene expression changes at the protein level.
Results: Docetaxel resistance was associated with changes in
DNA methyltransferase activity and global methylation. Treat-
ment with decitabine alone did not alter response to docetaxel.
In contrast, TSA enhanced docetaxel sensitivity in MCF-7
cells whereas MDA-MB-231 cells were unaffected. Combination
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treatment with decitabine and TSA increased docetaxel sensitiv-
ity in MCF-7 and MDA-MB-231 cells (P < 0.05). An array of 84 genes
identified 5 genes decreased in resistant cells whose expression
was upregulated after decitabine and TSA treatment (P < 0.05).
Western analysis confirmed expression changes in only one gene,
SERPINE1, in docetaxel-resistant cells.
Conclusions: Docetaxel resistance is associated with changes in
the DNA methylation machinery. Inhibiting DNA methylation and
histone deacetylation, in combination, overcomes resistance of
breast cancer cells to docetaxel. Our findings indicate that
decreased SERPINE1 expression is associated with docetaxel
resistance.
doi:10.1016/j.ejcsup.2010.06.012
O-12 TRANSLATIONAL EXPLORATION OF PIK3/Akt pathway
activation in early invasive breast cancer
Mohammed A. Aleskandarany, Emad A. Rakha, Mohammed A.
Ahmed, Des G. Powe, Ian O. Ellis, Andrew R. Green. Division of
Pathology, Nottingham University Hospitals and University of
Nottingham, Nottingham, UK
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a fre-
quently deregulated pathway in breast cancer (BC). Akt arguably
relays a plethora of extracellular signals to modulate diverse bio-
logic effects, including cell proliferation, growth, motility, and sur-
vival, downstream of PI3K activation. However, complexity and
diversity in the upstream/downstream arms of this pathway chal-
lenge considerably the clinical evolvement of effective therapies.
This study aims to study expressions of PIK3CA and phospho-
Akt1 (pAkt) in BC, with respect to proteins upstream/downstream
of Akt activation, clinicopathologic parameters, and disease out-
come. PIK3CA and pAkt (ser473) were evaluated by immunohisto-
chemistry on tissue microarrays containing 1202 early invasive
BC with long term follow-up.
In this study, pAkt overexpression was associated with patients’
age, estrogen and androgen receptors, cytokeratin (CK)18, CK19
and PTEN expression. Loss of pAkt was correlated with higher
grade, CK5/6, p53 and Ki-67 labelling index. Luminal-like tumours
displayed more pAkt positivity than triple negative/basal-like sub-
types. However, pAkt overexpression was not associated with
breast cancer-specific (BCSS) or metastasis-free survival (MFS).
Four combinatorial phenotypes were identified based on PIK3CA
and pAkt expression, with considerable proportions being
PIK3CA/pAkt+ or PIK3CA+/pAkt. These phenotypes were signifi-
cantly associated with BCSS (p = 0.001) and MFS (p = 0.002).
Although pAKT is an oncogene that correlated with poor prog-
nostic variables, it was not a prognostic marker. Combinatorial phe-
notypic groups of PIK3CA/pAkt denoted, at translational level,
functional complexity within the upstream and downstream net-
work of Akt activation with significant impact on patients’ outcome.
These findingsmay help developing adequate therapeutic regimens
against specific components of this key signalling pathway.
doi:10.1016/j.ejcsup.2010.06.013
O-13 D-gLUCURONYL C5-EPIMERASE INHIBITS BREAST CANCER
CELLS PROLIFERATION THROUGH THE TUMOUR SUPPRESSOR
GENES ACTIVATION
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Grigorieva a,b. a Institute of Molecular Biology and Biophysics,
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D-Glucuronyl C5-epimerase (GLCE) is one of the key enzymes
of the biosynthesis of heparan sulphate proteoglycans. Down-
regulation of GLCE expression in human breast tumours and can-
cer cell lines suggested a possible involvement of the gene in
breast carcinogenesis. To test the hypothesis, we ectopically
expressed GLCE in breast cancer cells MCF7 and showed that
re-expression of D-glucuronyl C5-epimerase significantly inhibited
proliferative activity of MCF7 cells according to CyQUANT NF Cell
Proliferation Assay and did not affect the viability of the cells in
Colony Formation Test. The antimitotic effect of D-glucuronyl C5-
epimerase in human breast cancer cells probably is realised via
the activation of tumour suppressor genes SYK (+8.1-fold), BRCA1
(+3.5-fold), p53 (+3.3-fold) and E2F1 (+3.00-fold) and change of a
balance of pro- and anti-apoptotic factors BCL2 (+4.2-fold), NFKB1
(+2.6-fold) and TNF (+4.6-fold) (PathFinder RT Profiler PCR Array).
Also, GLCE re-expression in MCF7 cells considerably changed
expression of some genes involved in angiogenesis (IL8, IFNB1,
TNF and TGFB1) and invasion/metastasis (SYK, NME1, S100A4)
suggesting a possible antimetastatic effect of GLCE in vivo.
In summary, the ability of the D-glucuronyl C5-epimerase to sup-
press proliferation of breast cancer cells through the affecting dif-
ferent key genes involved in cell cycle regulation, angiogenesis
and invasion/metastasis molecular pathways supposes the gene
as a new potential candidate for diagnosis and treatment of
breast cancer.
doi:10.1016/j.ejcsup.2010.06.014
O-14 EXPRESSION AND ACTIVATION OF Akt AND NFkB IN
BREAST CANCER PATIENTS
J. Edwards, C. Tannahill, C. Obondo, B. Elsberger, E. Mallon, C.
Wilson, J. Doughty. Western Infirmary/University of Glasgow,
Glasgow, UK
Background: It is postulated that Akt activates the Nf-kB
pathway to promote tumour growth and survival in breast cancer
cells.
Material and methods: Tissue microarray technology was
employed to analyse tissue from 426 breast cancer patients.
Immunohistochemistry was performed using antibodies for pAkt
(phosphorylated at serine 473), NF- kB and pNFkappaB (phosphor-
ylated at serine 536). Expression was assessed using the weighted
histoscore method by two independent scorers.
Results: Median age was 62 years, median tumour size was
20 mm, 48% were pathologically graded G2 and 31% G3 and 48%
were lymph node positive. Ninety-eight patients had unilateral
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